Several SARS-CoV-2 virus variants have emerged since the pandemic started. Alongside the threat of these emerging variants, the evidence for COVID-19 therapeutics has likewise grown.
In the last two years alone, several medications have been shown to prevent hospitalization among vulnerable groups who have non-severe COVID-19 infection. However, guidelines continue to change as some drugs are deemed ineffective for emerging COVID subvariants. This e-learning module reviews the most recent outpatient medications recommended by the WHO for non-severe COVID-19 infection, the mechanism of action of these drugs, their adverse effects, and summarizes the available evidence regarding these therapeutic options.
Upon completion of the educational activity, participants will be able to
Dr Zee Sze Tsing, Jonpaul
Specialist in Infectious Diseases
Keywords: COVID-19, COVID antivirals, nirmatrelvir ritonavir, molnupiravir, remdesivir, WHO recommendations